参麦注射液联合常规抗结核药物对肺结核患者的临床疗效、免疫功能及炎症因子水平的影响-现代医学

参麦注射液联合常规抗结核药物对肺结核患者的临床疗效、免疫功能及炎症因子水平的影响

单位：1. 重庆市公共卫生医疗救治中心感染一科, 重庆 400036;
2. 重庆市公共卫生医疗救治中心结核科, 重庆 400036;
3. 广州市第八人民医院感染科, 广东广州 510060

分类号：R256.13;R520.53

出版年·卷·期（页码）：2018·46·第十一期（1266-1270）

摘要：

目的：探讨参麦注射液联合常规抗结核药物对肺结核患者的临床疗效、免疫功能及炎症因子水平的影响。方法：选择本中心收治的86例肺结核患者，采用随机数字表法将其分为观察组和对照组，各43例。对照组给予常规抗结核药物进行治疗，观察组在对照组基础上联合应用参麦注射液进行治疗，对两组患者临床疗效、免疫功能及炎症因子水平进行对比分析。结果：治疗后观察组总有效率为88.37%，显著高于对照组的69.76%（P<0.05）。两组CD3⁺、CD4⁺、CD4⁺/CD8⁺的值较治疗前明显升高，而CD8⁺值显著降低，差异均有统计学意义（P<0.05）；观察组治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺的值较对照组明显升高，而CD8⁺值显著降低，差异均有统计学意义（P<0.05）。两组治疗前炎症因子各指标之间比较差异无统计学意义（P>0.05）；治疗后两组较治疗前各指标均下降，且观察组下降更明显，组间比较差异有统计学意义（P<0.05）。结论：常规抗结核药物对肺结核患者具有一定的临床治疗效果；对肺结核患者采取抗结核药物联合参麦注射液治疗措施，不仅可进一步提高临床治疗效果，而且还能在一定程度上提高患者的免疫功能，降低炎症因子的水平，其临床应用安全性较高，值得进一步推广。

Objective:The effects of Shenmai injection combined with conventional anti-tuberculosis drugs on clinical effect, immune function and inflammatory factor levels in patients with pulmonary tuberculosis were investigated. Methods:86 patients with pulmonary tuberculosis treated in the Department of pulmonary disease were divided into observation group and control group by random number table method, 43 cases in each group. The control group was treated with routine anti-tuberculosis drugs in hospital, while the observation group was additionally treated with Shenmai injection. The clinical efficacy, immune function and inflammatory factors of the two groups were compared and analyzed Results:After treatment, the total effective rate was 88.37% in the observation group, which was significantly higher than 69.76% in the control group. There was a statistically significant difference between the two groups(P<0.05). After treatment, the values of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ were significantly higher than those before treatment, but the CD8⁺ value was significantly decreased, and the difference was statistically significant(P<0.05). The CD3⁺, CD4⁺, and CD4⁺/CD8⁺ values in the observation group was also significantly higher than that of the control group, but the CD8⁺ value was significantly decreased, and the difference was statistically significant(P<0.05). There was no significant difference between the two groups before treatment in the indicators of inflammatory factors(P>0.05). After treatment, the two groups decreased compared with before treatment, and the observation group decreased more significantly. The difference between the two groups was statistically significant(P<0.05). Conclusion:Conventional anti-tuberculosis drugs have important clinical treatment significance for patients with pulmonary tuberculosis, however, when combined with Shenmai injection, not only can it further improve the clinical treatment effect, but also improve the patient's immune function and reduce the level of inflammatory factors to a certain extent. The safety of clinical application is high, so it is worthy of further application in clinic.

参考文献：

[1] 戈启萍,杜建,姜广路,等.标准复治化疗方案治疗多耐药与敏感复治肺结核患者的对比研究[J].中国防痨杂志,2015,31(8):879-884.
[2] 任郭侠,董琪,弓显凤,等.参麦注射液辅助治疗肺结核30例疗效观察[J].新中医,2011,29(10):81-82.
[3] 张春宝.手术联合标准化疗方案与标准化疗方案治疗耐多药肺结核病的对照研究[J].河北医药,2017,32(1):107-110.
[4] 蒋龄周.贞芪扶正颗粒联合抗结核药治疗肺结核临床疗效及对T淋巴细胞亚群的影响[J].中医药信息,2017,31(5):104-107.
[5] 李雪黎,温海平,桑俊,等.Xpert MTB/RIF在肺结核及耐药结核检测中的应用价值分析[J].国际检验医学杂志,2018,35(1):100-102.
[6] 王玲华,宋丽君,陆海阳,等.不同取痰法及痰液性状对机械通气肺结核患者Xpert MTB/RIF阳性检出率的影响[J].中华临床感染病杂志,2017,33(5):375-379,383.
[7] 杨莹,黄雪惠,彭湘汕.利福平注射液和参麦注射液治疗肺结核的近期效果观察[J].中国热带医学,2015,29(8):1017-1019.
[8] 刘宇红,高微微,李亮,等.单耐药和多耐药复治菌阳肺结核个体化治疗效果探讨[J].中华结核和呼吸杂志,2018,34(1):25-31.
[9] 闫壁松,高原.常规抗结核化疗方案联合中成药结核丸治疗肺结核的Meta分析[J].中国中医药科技,2017,33(4):533-536.
[10] 刘凡平,张晨钰,王云,等.全球基金标准化疗方案治疗耐多药肺结核临床疗效评价[J].河北医药,2016,31(7):1060-1062.
[11] 童维佳,王洁,陆磊,等.个体化抗结核治疗对肺结核合并慢性HBV感染患者肝功能的影响[J].广西医学,2018,29(3):266-268.
[12] 杨莹,黄雪惠,彭湘汕.利福平联合参麦注射用药治疗肺结核的近期疗效观察[J].中国药业,2016,34(15):86-88.
[13] 范任华,向延根,杨励,等.多耐药肺结核患者特异性细胞免疫失衡与调节性T细胞CD4⁺CD25⁺CD127^low有关[J].东南大学学报(医学版),2015,34(4):525-531.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录